Dr. Reddys launches Carboprost Tromethamine Injection USP

Dr. Reddy’s Laboratories Limited has announced the launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial, a therapeutic equivalent generic version of Hemabate injection, 250 mcg/mL, approved by the US Food and Drug Administration (USFDA).

The management of the company informed that with a CGT designation, it has 180-day CGT exclusivity to market this product.

According to IQVIA Health, the Hemabate injection, 250 mcg/mL brand had U.S. sales of approximately US$55 million MAT for the most recent twelve months ending in April 2019.

Dr. Reddy's Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) contains carboprost tromethamine equivalent to 250 mcg of carboprost.

Last month, the company has launched Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI (tobramycin) Inhalation Solution, approved by USFDA.

Dr. Reddy’s Laboratories is a pharmaceutical company having segments like Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products.

On Wednesday, the stock of Dr. Reddy’s Laboratories opened at Rs. 2,630 per share. During the day, the stock has dipped by 1.8 per cent making intra day low of Rs. 2,581 per share.